Literature DB >> 31763103

Outcomes of Multi-disciplinary Management of Metastatic Renal Cell Carcinoma.

Michael Yan1, Richard Gregg2, Aamer Mahmud3.   

Abstract

Metastatic renal cell carcinoma (mRCC) is associated with a poor prognosis. It is traditionally a treatment-resistant disease necessitating multi-modal treatment and close follow-up. We herein report a case of mRCC in a patient who was managed closely by a multi-disciplinary team and still retained a very good performance status and treatment response three years after diagnosis. We highlight the importance of close monitoring, switching systemic therapies at progression, early palliative radiotherapy, and patient education in controlling disease burden and maintaining quality of life in patients with mRCC.
Copyright © 2019, Yan et al.

Entities:  

Keywords:  metastatic disease; multi-disciplinary; palliative care; radiotherapy; renal cell carcinoma

Year:  2019        PMID: 31763103      PMCID: PMC6850746          DOI: 10.7759/cureus.5901

Source DB:  PubMed          Journal:  Cureus        ISSN: 2168-8184


  15 in total

Review 1.  Renal-cell carcinoma.

Authors:  R J Motzer; N H Bander; D M Nanus
Journal:  N Engl J Med       Date:  1996-09-19       Impact factor: 91.245

2.  Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.

Authors:  Robert J Motzer; Thomas E Hutson; Piotr Tomczak; M Dror Michaelson; Ronald M Bukowski; Olivier Rixe; Stéphane Oudard; Sylvie Negrier; Cezary Szczylik; Sindy T Kim; Isan Chen; Paul W Bycott; Charles M Baum; Robert A Figlin
Journal:  N Engl J Med       Date:  2007-01-11       Impact factor: 91.245

Review 3.  Multimodal treatment of advanced renal cancer in 2017.

Authors:  Alessia Mennitto; Elena Verzoni; Paolo Grassi; Raffaele Ratta; Giovanni Fucà; Giuseppe Procopio
Journal:  Expert Rev Clin Pharmacol       Date:  2017-10-06       Impact factor: 5.045

4.  A phase II trial of palliative radiotherapy for metastatic renal cell carcinoma.

Authors:  Justin Lee; David Hodgson; Edward Chow; Andrea Bezjak; Pamela Catton; Debbie Tsuji; Mary O'Brien; Cyril Danjoux; Charles Hayter; Padraig Warde; Mary K Gospodarowicz
Journal:  Cancer       Date:  2005-11-01       Impact factor: 6.860

5.  Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.

Authors:  Robert J Motzer; Nizar M Tannir; David F McDermott; Osvaldo Arén Frontera; Bohuslav Melichar; Toni K Choueiri; Elizabeth R Plimack; Philippe Barthélémy; Camillo Porta; Saby George; Thomas Powles; Frede Donskov; Victoria Neiman; Christian K Kollmannsberger; Pamela Salman; Howard Gurney; Robert Hawkins; Alain Ravaud; Marc-Oliver Grimm; Sergio Bracarda; Carlos H Barrios; Yoshihiko Tomita; Daniel Castellano; Brian I Rini; Allen C Chen; Sabeen Mekan; M Brent McHenry; Megan Wind-Rotolo; Justin Doan; Padmanee Sharma; Hans J Hammers; Bernard Escudier
Journal:  N Engl J Med       Date:  2018-03-21       Impact factor: 91.245

6.  Survival after complete surgical resection of multiple metastases from renal cell carcinoma.

Authors:  Angela L Alt; Stephen A Boorjian; Christine M Lohse; Brian A Costello; Bradley C Leibovich; Michael L Blute
Journal:  Cancer       Date:  2011-01-10       Impact factor: 6.860

7.  Resection of metastatic renal cell carcinoma.

Authors:  J P Kavolius; D P Mastorakos; C Pavlovich; P Russo; M E Burt; M S Brady
Journal:  J Clin Oncol       Date:  1998-06       Impact factor: 44.544

8.  Pazopanib versus sunitinib in metastatic renal-cell carcinoma.

Authors:  Robert J Motzer; Thomas E Hutson; David Cella; James Reeves; Robert Hawkins; Jun Guo; Paul Nathan; Michael Staehler; Paul de Souza; Jaime R Merchan; Ekaterini Boleti; Kate Fife; Jie Jin; Robert Jones; Hirotsugu Uemura; Ugo De Giorgi; Ulrika Harmenberg; Jinwan Wang; Cora N Sternberg; Keith Deen; Lauren McCann; Michelle D Hackshaw; Rocco Crescenzo; Lini N Pandite; Toni K Choueiri
Journal:  N Engl J Med       Date:  2013-08-22       Impact factor: 91.245

9.  Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.

Authors:  Robert J Motzer; Bernard Escudier; David F McDermott; Saby George; Hans J Hammers; Sandhya Srinivas; Scott S Tykodi; Jeffrey A Sosman; Giuseppe Procopio; Elizabeth R Plimack; Daniel Castellano; Toni K Choueiri; Howard Gurney; Frede Donskov; Petri Bono; John Wagstaff; Thomas C Gauler; Takeshi Ueda; Yoshihiko Tomita; Fabio A Schutz; Christian Kollmannsberger; James Larkin; Alain Ravaud; Jason S Simon; Li-An Xu; Ian M Waxman; Padmanee Sharma
Journal:  N Engl J Med       Date:  2015-09-25       Impact factor: 91.245

10.  Renal cell carcinoma recurrences and metastases in primary non-metastatic patients: a population-based study.

Authors:  Saeed Dabestani; Andreas Thorstenson; Per Lindblad; Ulrika Harmenberg; Börje Ljungberg; Sven Lundstam
Journal:  World J Urol       Date:  2016-02-05       Impact factor: 4.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.